DE60033519T2 - Morphinsulfat enthaltende mikrogranulate, verfahren zu deren herstellung und pharmazeutische zusammensetzungen - Google Patents
Morphinsulfat enthaltende mikrogranulate, verfahren zu deren herstellung und pharmazeutische zusammensetzungen Download PDFInfo
- Publication number
- DE60033519T2 DE60033519T2 DE60033519T DE60033519T DE60033519T2 DE 60033519 T2 DE60033519 T2 DE 60033519T2 DE 60033519 T DE60033519 T DE 60033519T DE 60033519 T DE60033519 T DE 60033519T DE 60033519 T2 DE60033519 T2 DE 60033519T2
- Authority
- DE
- Germany
- Prior art keywords
- microgranules
- morphine sulfate
- layer
- sustained release
- neutral carrier
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000000034 method Methods 0.000 title claims description 8
- 238000002360 preparation method Methods 0.000 title claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 3
- 239000000203 mixture Substances 0.000 claims description 28
- GRVOTVYEFDAHCL-RTSZDRIGSA-N morphine sulfate pentahydrate Chemical compound O.O.O.O.O.OS(O)(=O)=O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O GRVOTVYEFDAHCL-RTSZDRIGSA-N 0.000 claims description 25
- 229960004715 morphine sulfate Drugs 0.000 claims description 21
- 230000007935 neutral effect Effects 0.000 claims description 19
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 18
- 238000013268 sustained release Methods 0.000 claims description 12
- 239000012730 sustained-release form Substances 0.000 claims description 12
- 230000003111 delayed effect Effects 0.000 claims description 11
- 230000002209 hydrophobic effect Effects 0.000 claims description 9
- 239000000377 silicon dioxide Substances 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 229920001577 copolymer Polymers 0.000 claims description 7
- 229920003134 Eudragit® polymer Polymers 0.000 claims description 6
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims description 6
- 239000000314 lubricant Substances 0.000 claims description 6
- 239000004014 plasticizer Substances 0.000 claims description 6
- 239000011230 binding agent Substances 0.000 claims description 5
- 239000004531 microgranule Substances 0.000 claims description 5
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims description 4
- 239000001069 triethyl citrate Substances 0.000 claims description 4
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims description 4
- 235000013769 triethyl citrate Nutrition 0.000 claims description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 125000004185 ester group Chemical group 0.000 claims description 2
- 239000008187 granular material Substances 0.000 description 21
- 238000009472 formulation Methods 0.000 description 16
- 239000002775 capsule Substances 0.000 description 13
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 11
- 238000000338 in vitro Methods 0.000 description 9
- 239000011248 coating agent Substances 0.000 description 8
- 238000000576 coating method Methods 0.000 description 8
- 229920000642 polymer Polymers 0.000 description 8
- 238000004090 dissolution Methods 0.000 description 6
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 5
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 5
- 230000036470 plasma concentration Effects 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 229960005181 morphine Drugs 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000007922 dissolution test Methods 0.000 description 3
- 238000013112 stability test Methods 0.000 description 3
- 229910002012 Aerosil® Inorganic materials 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 2
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 2
- 229940117841 methacrylic acid copolymer Drugs 0.000 description 2
- 229920000058 polyacrylate Polymers 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- FOJYFDFNGPRXDR-SQILNHJXSA-N (4r,4ar,7s,7ar,12bs)-10-[(4r,4ar,7s,7ar,12bs)-7,9-dihydroxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-10-yl]-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7,9-diol Chemical compound C([C@H]12)=C[C@H](O)[C@@H]3OC4=C(O)C(C=5C=C6C7=C(C=5O)O[C@@H]5[C@]77CCN([C@H](C6)[C@@H]7C=C[C@@H]5O)C)=CC5=C4[C@]13CCN(C)[C@@H]2C5 FOJYFDFNGPRXDR-SQILNHJXSA-N 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 229920003161 Eudragit® RS 30 D Polymers 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- FOJYFDFNGPRXDR-UHFFFAOYSA-N Pseudomorphine Natural products C12C=CC(O)C3OC4=C(O)C(C=5C=C6C7=C(C=5O)OC5C77CCN(C(C6)C7C=CC5O)C)=CC5=C4C23CCN(C)C1C5 FOJYFDFNGPRXDR-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229920006243 acrylic copolymer Polymers 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 229920013820 alkyl cellulose Polymers 0.000 description 1
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 1
- 229960004046 apomorphine Drugs 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 230000009477 glass transition Effects 0.000 description 1
- 229920013821 hydroxy alkyl cellulose Polymers 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000003232 mucoadhesive effect Effects 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/501—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Inorganic Chemistry (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9907259A FR2794646B1 (fr) | 1999-06-09 | 1999-06-09 | Microgranules de sulfate de morphine, procede de preparation et composition les contenant |
| FR9907259 | 1999-06-09 | ||
| PCT/FR2000/001573 WO2000074659A1 (fr) | 1999-06-09 | 2000-06-08 | Microgranules de sulfate de morphine, procede de preparation et composition les contenant |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE60033519D1 DE60033519D1 (de) | 2007-04-05 |
| DE60033519T2 true DE60033519T2 (de) | 2007-10-31 |
Family
ID=9546553
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60033519T Expired - Lifetime DE60033519T2 (de) | 1999-06-09 | 2000-06-08 | Morphinsulfat enthaltende mikrogranulate, verfahren zu deren herstellung und pharmazeutische zusammensetzungen |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US7063864B1 (enExample) |
| EP (3) | EP1189602B1 (enExample) |
| JP (1) | JP4296562B2 (enExample) |
| KR (1) | KR100676123B1 (enExample) |
| CN (1) | CN1267089C (enExample) |
| AR (2) | AR024313A1 (enExample) |
| AT (2) | ATE354356T1 (enExample) |
| AU (1) | AU769160C (enExample) |
| BR (1) | BRPI0011404B8 (enExample) |
| CA (1) | CA2376339C (enExample) |
| CO (1) | CO5160317A1 (enExample) |
| CY (1) | CY1107612T1 (enExample) |
| DE (1) | DE60033519T2 (enExample) |
| DK (2) | DK1189602T3 (enExample) |
| ES (2) | ES2280226T3 (enExample) |
| FR (1) | FR2794646B1 (enExample) |
| HK (1) | HK1045107B (enExample) |
| MX (1) | MXPA01012751A (enExample) |
| NZ (1) | NZ516077A (enExample) |
| PT (2) | PT1627631E (enExample) |
| SI (1) | SI1189602T1 (enExample) |
| TW (1) | TWI224510B (enExample) |
| WO (1) | WO2000074659A1 (enExample) |
| ZA (1) | ZA200110087B (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2794646B1 (fr) * | 1999-06-09 | 2001-09-21 | Ethypharm Lab Prod Ethiques | Microgranules de sulfate de morphine, procede de preparation et composition les contenant |
| JP4848101B2 (ja) * | 2001-08-17 | 2011-12-28 | 株式会社フジモト・コーポレーション | 徐放性マイクロペレット |
| EP1429739A1 (en) | 2001-09-21 | 2004-06-23 | Egalet A/S | Polymer release system |
| EP1429744A1 (en) | 2001-09-21 | 2004-06-23 | Egalet A/S | Morphine polymer release system |
| DE602004031096D1 (de) | 2003-03-26 | 2011-03-03 | Egalet As | Morphin-system mit kontrollierter freisetzung |
| FR2883179B1 (fr) * | 2005-03-18 | 2009-04-17 | Ethypharm Sa | Comprime enrobe |
| US20100233257A1 (en) * | 2006-06-09 | 2010-09-16 | Ethypharm | Low dose sublingual tablets of opioid analgesics and preparation process |
| US20070286900A1 (en) * | 2006-06-09 | 2007-12-13 | Catherine Herry | Low dose tablets of opioid analgesics and preparation process |
| CA2687192C (en) | 2007-06-04 | 2015-11-24 | Egalet A/S | Controlled release pharmaceutical compositions for prolonged effect |
| NZ594207A (en) | 2009-02-06 | 2013-03-28 | Egalet Ltd | Immediate release composition resistant to abuse by intake of alcohol |
| NZ597283A (en) | 2009-06-24 | 2013-07-26 | Egalet Ltd | Controlled release formulations |
| US20190038769A1 (en) * | 2010-12-01 | 2019-02-07 | Gowey Research Group, Pllc | Micro-rna profiling, compositions, and methods of treating diseases |
| JP2012250926A (ja) * | 2011-06-01 | 2012-12-20 | Nitto Denko Corp | 粒子製剤 |
| US9549899B2 (en) | 2012-07-06 | 2017-01-24 | Egalet Ltd. | Abuse deterrent pharmaceutical compositions for controlled release |
| IL273627B2 (en) | 2017-12-20 | 2025-03-01 | Purdue Pharma Lp | Morphine sulfate dosage forms for abuse deterrence |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8514665D0 (en) | 1985-06-11 | 1985-07-10 | Eroceltique Sa | Oral pharmaceutical composition |
| CA2007181C (en) | 1989-01-06 | 1998-11-24 | Angelo Mario Morella | Sustained release pharmaceutical composition |
| US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
| GB9117361D0 (en) * | 1991-08-12 | 1991-09-25 | Euro Celtique Sa | Oral dosage form |
| GB9119958D0 (en) | 1991-09-18 | 1991-10-30 | Unilever Plc | Detergent compositions |
| US5286493A (en) | 1992-01-27 | 1994-02-15 | Euroceltique, S.A. | Stabilized controlled release formulations having acrylic polymer coating |
| US5968551A (en) * | 1991-12-24 | 1999-10-19 | Purdue Pharma L.P. | Orally administrable opioid formulations having extended duration of effect |
| US5478577A (en) * | 1993-11-23 | 1995-12-26 | Euroceltique, S.A. | Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| SE9301057L (sv) | 1993-03-30 | 1994-10-01 | Pharmacia Ab | Beredning med kontrollerad frisättning |
| HU218673B (hu) * | 1993-10-07 | 2000-10-28 | Euroceltique S.A. | Opioid analgetikumot tartalmazó elnyújtott hatóanyag-felszabadítású orális gyógyszerkészítmény és eljárás előállítására |
| US5411745A (en) | 1994-05-25 | 1995-05-02 | Euro-Celtique, S.A. | Powder-layered morphine sulfate formulations |
| US5460826A (en) | 1994-06-27 | 1995-10-24 | Alza Corporation | Morphine therapy |
| GB9422154D0 (en) | 1994-11-03 | 1994-12-21 | Euro Celtique Sa | Pharmaceutical compositions and method of producing the same |
| FR2771291B1 (fr) * | 1997-11-21 | 2000-02-25 | Ethypharm Lab Prod Ethiques | Spheroides, procede de preparation et compositions pharmaceutiques |
| FR2794646B1 (fr) * | 1999-06-09 | 2001-09-21 | Ethypharm Lab Prod Ethiques | Microgranules de sulfate de morphine, procede de preparation et composition les contenant |
-
1999
- 1999-06-09 FR FR9907259A patent/FR2794646B1/fr not_active Expired - Lifetime
-
2000
- 2000-06-06 CO CO00041883A patent/CO5160317A1/es unknown
- 2000-06-07 AR ARP000102831A patent/AR024313A1/es not_active Application Discontinuation
- 2000-06-08 DK DK00940460T patent/DK1189602T3/da active
- 2000-06-08 HK HK02105909.7A patent/HK1045107B/zh unknown
- 2000-06-08 NZ NZ516077A patent/NZ516077A/en not_active IP Right Cessation
- 2000-06-08 MX MXPA01012751A patent/MXPA01012751A/es active IP Right Grant
- 2000-06-08 BR BRPI0011404A patent/BRPI0011404B8/pt not_active IP Right Cessation
- 2000-06-08 ES ES00940460T patent/ES2280226T3/es not_active Expired - Lifetime
- 2000-06-08 JP JP2001501196A patent/JP4296562B2/ja not_active Expired - Lifetime
- 2000-06-08 DE DE60033519T patent/DE60033519T2/de not_active Expired - Lifetime
- 2000-06-08 SI SI200030946T patent/SI1189602T1/sl unknown
- 2000-06-08 EP EP00940460A patent/EP1189602B1/fr not_active Expired - Lifetime
- 2000-06-08 ES ES05111290T patent/ES2379688T3/es not_active Expired - Lifetime
- 2000-06-08 AT AT00940460T patent/ATE354356T1/de active
- 2000-06-08 PT PT05111290T patent/PT1627631E/pt unknown
- 2000-06-08 CN CNB008086052A patent/CN1267089C/zh not_active Expired - Lifetime
- 2000-06-08 KR KR1020017015784A patent/KR100676123B1/ko not_active Expired - Lifetime
- 2000-06-08 DK DK05111290.2T patent/DK1627631T3/da active
- 2000-06-08 WO PCT/FR2000/001573 patent/WO2000074659A1/fr not_active Ceased
- 2000-06-08 US US10/009,341 patent/US7063864B1/en not_active Expired - Lifetime
- 2000-06-08 CA CA2376339A patent/CA2376339C/fr not_active Expired - Lifetime
- 2000-06-08 PT PT00940460T patent/PT1189602E/pt unknown
- 2000-06-08 AU AU55394/00A patent/AU769160C/en not_active Expired
- 2000-06-08 AT AT05111290T patent/ATE544448T1/de active
- 2000-06-08 EP EP05111290A patent/EP1627631B1/fr not_active Expired - Lifetime
- 2000-06-08 EP EP07102671A patent/EP1818051A1/fr not_active Withdrawn
- 2000-06-27 TW TW089111207A patent/TWI224510B/zh not_active IP Right Cessation
-
2001
- 2001-12-07 ZA ZA200110087A patent/ZA200110087B/xx unknown
-
2006
- 2006-05-26 US US11/441,349 patent/US20070003620A1/en not_active Abandoned
-
2007
- 2007-04-05 CY CY20071100489T patent/CY1107612T1/el unknown
-
2008
- 2008-08-22 AR ARP080103672A patent/AR068015A2/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69430491T2 (de) | Verfahren zur verkapselung von nsaids | |
| DE69919713T2 (de) | Pharmazeutische zubereitung mit verzögerter wirkstofffreisetzung von phenytoin natrium | |
| DE69529050T2 (de) | Orale dosierungsformen mit pulverschicht | |
| DE69331906T2 (de) | Granulierte pharmazeutische zusammensetzung | |
| DE69423028T3 (de) | Zubereitung mit kontrollierter freisetzung, die ein morphinsalz enthält | |
| DE69721845T2 (de) | Orale morphinzubereitung in teilchenform | |
| DE69427568T2 (de) | Rasch freisetzende Tablettenkerne mit unlöslichen Arzneistoffen und mit einem Retardüberzug | |
| DE69626397T2 (de) | Darifenacin enthaltende pharmazeutische zubereitungen | |
| DE69727386T2 (de) | Geschmacksmaskierte flüssige suspensionen | |
| DE3785167T2 (de) | Eine fluessige verabreichungsform fuer orale verabreichung einer pharmazeutischen substanz. | |
| EP0977557B1 (de) | Pellet-formulierung zur behandlung des intestinaltraktes | |
| DE69634160T2 (de) | Ein säurelabile Omeprazol enthaltende Arzneizusammensetzung und Verfahren zu deren Herstellung | |
| DE69032445T2 (de) | Arzneimittel mit verzögerter Freigabe | |
| DE69622510T2 (de) | Nifedipinzubereitung mit langanhaltender Freisetzung | |
| DE69630215T2 (de) | Diltiazem-formulierung mit gesteuerter freigabe | |
| DE69111832T2 (de) | Naproxen-Formulierung zur kontrollierten Absorption zur einmal täglichen Anwendung. | |
| DE69205971T2 (de) | Orale dosierungsform mit verzögerter wirkstoffabgabe für die behandlung von intestinalen krankheiten. | |
| DE3751860T2 (de) | Verwendung von spezifischem Kernmaterial und Schichten zur Herstellung pharmazeutischer Formulierungen, die stabil gegen die Verfärbung von Omeprazol sind | |
| DE3877492T2 (de) | Pharmazeutisches praeparat mit verzoegerter abgabe eines dihydropyridins und eines beta-adrenorezeptor-antagonisten und herstellungsverfahren dessen. | |
| DE60033519T2 (de) | Morphinsulfat enthaltende mikrogranulate, verfahren zu deren herstellung und pharmazeutische zusammensetzungen | |
| DE69811278T2 (de) | Gegen magensaft geschützte omeprazol-mikrogranülen, herstellungsverfahren und pharmazeutische zubereitungen | |
| DE60108255T2 (de) | Clarithromycin enthaltende zubereitung mit verlängerter freisetzung | |
| DE69324214T2 (de) | Pharmazeutische flüssige Suspensionszusammensetzung mit kontrollierter Freigabe | |
| CH705678B1 (de) | Verwendung von Bindemitteln zur Herstellung von lagerungsstabilen Formulierungen. | |
| EP0551820A1 (de) | Geschmacksmaskierte pharmazeutische Mittel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |